Curative Biosciences, Inc.
CBDX
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -92.91% | 2,775.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -92.91% | 2,603.59% | |||
| Operating Income | 92.91% | -2,603.59% | |||
| Income Before Tax | 92.91% | -2,603.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 92.91% | -2,603.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 92.91% | -2,603.59% | |||
| EBIT | 92.91% | -2,603.59% | |||
| EBITDA | 93.01% | -2,717.50% | |||
| EPS Basic | 94.31% | -2,454.55% | |||
| Normalized Basic EPS | 94.29% | -2,400.00% | |||
| EPS Diluted | 94.31% | -2,454.55% | |||
| Normalized Diluted EPS | 94.29% | -2,400.00% | |||
| Average Basic Shares Outstanding | 21.69% | 2.41% | |||
| Average Diluted Shares Outstanding | 21.69% | 2.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||